Dr. Schmidt on Quadruplet Therapy for Newly Diagnosed, Transplant Ineligible MM
By Blood Cancer Talks - Last Updated: September 5, 2024In this episode of “Blood Cancer Talks,” hosts Ashwin Kishtagari, MD; Edward Cliff, MD; and Raj Chakraborty, MD, are joined by guest Timothy Schmidt, MD, of UW Health, to discuss quadruplet therapy for the management of newly diagnosed, transplant ineligible multiple myeloma (MM).
The episode discusses the following trials:
- MAIA trial (DRd vs Rd)
- S0777 trial (VRd vs Rd)
- IMROZ trial (isatuximab-VRd vs VRd)
- IFM-2020/BENEFIT trial (isatuximab-VRd vs isatuximab-Rd)
- GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd)
This podcast originally appeared on Blood Cancer Talks.
Advertisement
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.